Sentynl will obtain full rights to Progerinin after specified milestones, while immediately collaborating with PRG S&T to accelerate clinical development for HGPS. Progerinin is designed to inhibit ...

Sentynl will acquire full rights to the investigational drug candidate, Progerinin (SLC-D011), adding to its commercial portfolio of rare and ultra-rare disease products AHMEDABAD, India and SOLANA ...

The Progeria Research Foundation ("PRF"), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome ("Progeria"), and Forge Biologics, ...

Progeria is an extremely rare genetic disease of childhood characterised by dramatic, premature ageing. The condition, which derives its name from “geras”, the Greek word for old age, is estimated to ...

Progeria, an ultrarare and fatal genetic disease characterized by rapid aging, can affect children and young adults.

Sentynl will acquire full rights to Progerinin for HGPS, provided certain milestones are achieved.

In the spring of 2005, families affected by progeria welcomed the news from two studies that uncovered new information about this rare, devastating condition that causes premature aging in children.

(Gray News) – The longest-living survivor of progeria has died at the age of 28. In a Facebook post, the Progeria Research Foundation announced that Sammy Basso passed away Saturday. “Sammy was the ...